PT-141 (Bremelanotide) vs GHK-Cu (Copper Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays important roles in wound healing, tissue repair, and has shown anti-aging properties in research.
Full details →Side-by-Side Comparison
| Aspect | PT-141 (Bremelanotide) | GHK-Cu (Copper Peptide) |
|---|---|---|
| Mechanism | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. | Attracts immune cells and fibroblasts to wound sites, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and has antioxidant effects. Modulates gene expression related to tissue repair. |
| Typical Dosage | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. | Topical: Applied as serum or cream 1-2 times daily. Injectable: 1-2mg daily for research purposes. Microneedling protocols often use 0.5-1%. |
| Administration | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. | Most commonly used topically for skin applications. Can be injected subcutaneously for systemic effects. Often combined with microneedling for enhanced skin penetration. |
| Side Effects | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. | Topical use is generally well-tolerated. May cause temporary skin irritation or redness in sensitive individuals. Injectable use may cause injection site reactions. |
| Best For |
What They Have in Common
Both PT-141 (Bremelanotide) and GHK-Cu (Copper Peptide) are commonly used for: